Mersana inks $1 billion plus deal with Janssen on ADCs
US biopharma firm Mersana Therapeutics’ (Nasdaq: MRSN) shot up 9% to $4.67 in early trading, after it announced a research collaboration and license agreement with Janssen Biotech, a part of healthcare giant Johnson & Johnson (NYSE: JNJ), to discover novel antibody drug conjugates (ADCs) for three targets. The agreement was facilitated by Johnson & Johnson Innovation.
Under the terms of the accord, Janssen will provide proprietary antibodies for three targets. Mersana will apply its expertise and its proprietary Dolasynthen platform to discover novel ADC product candidates. Mersana may leverage Synaffix’ GlycoConnect technology as its preferred site-specific ADC bioconjugation technology. Mersana will collaborate with Janssen on target candidates during preclinical development, with Janssen being solely responsible for clinical development and commercialization.
Financial terms of the deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze